Drug Discovery Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Drug Discovery Market

Advancements in the field of biotechnology and pharmaceuticals, in order to identify active ingredients in the form of drugs through drug discovery process, is gradually gaining pace in the market. This drug discovery process involves screening of chemical libraries, identification of the active ingredients for a natural remedy or by serendipitous discovery. Emergence of new diseases, which include viral or infectious diseases leads to high demand for drug discovery for these conditions. However, development of drugs is complex, costly, and risky process.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1631

The objective of drug discovery is to recognize the investigational drug success rates by stages, pre-clinical studies, investigational new drug application-Phase I, Phase II, Phase III studies, new drug application, and phase IV studies. The success during drug discovery process is very low, as according to data published by Journal Research & Review 2016. According to the data, it was estimated that among 5,000-10,000 drug discovery screening, only 250 enter the preclinical testing and 5 enter the clinical testing and only 1 drug is approved by the regulatory body, which takes roughly 5-10 years.

Furthermore, according to the same source, drug discovery process takes around 5-10 years for the complete drug discovery, development, and introduction in the market, which costs around US$1.7 Bn for complete process to undergo successfully.

Drug Discovery Market Dynamics:

A patent cliff provides an opportunity for manufactures to collaborate and participate in current drug discovery model to sustain in the market. Manufacturers such as, Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead lost their patent in 2017, with some of their respective big sellers that cover a range of indications such as multiple sclerosis, HIV, erectile dysfunction, and cancer. Such patent loss forces companies to introduce innovative products to retain their revenues and increase their revenue. After patent expiration, generic manufacturers enter the market and provide drugs that are equivalent to the innovator’s drugs, however, at a significantly lower price. Therefore, manufacturers are focusing on developing new and innovative products to sustain in the competitive market.

Increasing prevalence of wide range of disease such as cancer, cardiovascular, and CNS-related disorders with patent expiration of blockbuster drugs are some of the driving factors for growth of the drug discovery market. According to the World Cancer Research Fund International, 2015, an estimated 124,000 new cases of myeloma were diagnosed globally in 2015, which accounted for 0.8% of the total cancer cases. The mortality rate of the disease is around 0.9% of all cancer deaths, accounting for 87,000 deaths each year. Therefore, key manufacturers are actively involved in the development of immunotherapies targeting B-cell maturation antigen (BCMA) such as chimeric antigen receptor T-cells (CAR-T cells), bispecific antibodies, and antibody drug conjugates (ADCs). For instance, in 2012, the University of Pennsylvania and Novartis entered into an exclusive global research and licensing agreement to study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies. In 2016, Juno Therapeutics entered into a licensing agreement with Memorial Sloan Kettering Cancer Center (MSKCC) and Eureka Therapeutics for developing CAR T cell immunotherapy against multiple novel targets.

Drug Discovery Market - Regional Insights:

North America accounted for the largest share in the drug discovery market, followed by Europe market in 2016. This is attributed to presence of a large number of top pharmaceutical and biotech companies, Pfizer, Inc., Merck, GlaxoSmithKline, Novartis and many more in this region. Furthermore, favorable regulatory framework and regulatory policies for investors for research and development of new drugs augments growth of drug discovery market in the region. The US Regulatory Framework provides for 3 distinct regulatory approval pathways outlined in the Food, Drug, and Cosmetics Act (FD&C Act), which allows the registration of novel compounds, new drugs containing similar ingredients to previously approved products and generic copies of previously approved products in systematic way helping the pharmaceutical companies to gain approval over the new drugs.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/drug-discovery-market-1631

Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding in Asia Pacific region, to maximize on their R&D efforts as the Asia Pacific region provides better access to patients for clinical trials, with lower cost operational efficiencies. Increasing government investment in research and development is also expected to foster growth of drug discovery in Asia Pacific region. For instance, in March 2011, the Korean government participated in the Korean National Enterprise for Clinical Trials, to advance the country’s infrastructure for conducting clinical trials, which could fasten the process of clinical trials, in turn supporting the growth of drug discovery market.

Drug Discovery Market - Competitive Analysis:

• Pfizer Inc.
• GlaxoSmithKline LLC
• Merck & Co. Inc.
• Agilent Technologies Inc.
• Eli Lilly and Company
• F Hoffmann-La Roche Ltd
• Bayer AG
• Abbott Laboratories Inc.
• AstraZeneca PLC
• Shimadzu Corp.

Drug Discovery Market Taxonomy:

By Drug Type:

• Small Molecule Drug
• Biologics Drug

By Technology:

• High Throughput Screening
• Biochips
• Bioinformatics
• Pharmacogenomics and Pharmacogenetics
• Combinatorial Chemistry
• Nanotechnology
• Spectroscopy
• Metabolomics
• Other Technologies

By Services:

• Drug Metabolism and Pharmacokinetics (DMPK) Services
• Pharmaceutical Services
• Chemical Services
• Biological Services

By End User

• Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Other End Users

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Inquire Here Before Purchase Of This Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1631

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Stethoscope Market - Global Industry Insights, Trends, Outlook and Opportunity Analysis 2018-2026

Stethoscope Market

Stethoscope is an acoustic medical device used for auscultation based physical examination of an animal or humans. The resonator placed beneath the small disc at one end amplifies sound of lungs, heart, esophagus or fetal heart rate. Stethoscope is a fundamental component of physical examination for a healthcare profession. Major drivers for growth of the stethoscope market are increasing incidence of cardiovascular disease, rising number of healthcare professionals, and improving healthcare facilities. Moreover, market players are introducing more user friendly technologically advanced products with Bluetooth connectivity or wireless digital stethoscope, which is expected to boost growth of the stethoscope market.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1613

Stethoscope Market Drivers:

Increasing product launches by key players with advanced technologies is expected to aid in growth of the global stethoscope market during the forecast period. For instance, in March 2018, a research team developed an open-source, clinically validated template for a 3D printed stethoscope for application in the areas that have limited access to medical supplies. Moreover, in April 2018, Steth IO launched digital stethoscope named Steth IO. The product is built directly into the protective case of the physician’s iphone. It runs on an app that allows visualization of heart or lung sounds directly on the phone’s screen, when held against patient’s chest. Furthermore, it enables physician to store the records in the app, which can be shared in case of a second opinion. Steth IO received FDA approval in 2016. In 2015, Eko received US FDA clearance to launch Eko Core, a next generation digital stethoscope.

In January 2018, M3DICINE Inc., a designer of intelligent medical devices, launched Stethee, the first Artificially Intelligent (AI)-enabled stethoscope system. The Stethee system include three products, which are Stethee Pro for medical and healthcare professionals, Stethee Vet for veterinarians and animal professionals, and Stethee Edu developed as educational and research tool. All these product launches are technologically advanced versions of conventional stethoscope and is expected to increase choices for the users.

High incidence of heart diseases is expected to be another factor for growth of the market. Stethoscope is an important component that aids clinicians in diagnosis of cardiovascular disease, which affects 1 in 4 people in US, according to Center for Disease Control and Prevention (CDC). According to American Heart Association, 2018, cardiovascular disease is the leading cause of death, globally. Furthermore, according to same source, it is estimated that everyday 2,300 people in the U.S. die of cardiovascular disease, which means on an average 1 death per 38 seconds. Moreover, increasing geriatric population, who are more prone to diseases rising the demand for frequent diagnosis under several medical conditions expected to propel the growth of stethoscope market. For instance, the global geriatric population is estimated to be 962 million, which comprises 13% of the total global population, in 2017 as per United Nation Organization. According to their forecast, this geriatric population worldwide is expected to be reach 1.4 billion in 2030 and 2.1 billion by 2050.

Stethoscope Market - Regional Analysis:

Based on geography, the stethoscope market has been segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds the dominant position in stethoscope market, owing to the increasing number of new product launches by the key players in U.S. North America market is followed by Europe attributed to the increasing number of hospitals and clinics and medical professionals. For instance, according to Eurostat, around 1.8 million physicians are working in the European Union, while the comparison between 2005 and 2015 showed that the number of medical doctors graduating per 100,000 inhabitants rose to 12.4 medical doctors in 2015 as compared to 2005 (9.5 medical doctors per 100,00 inhabitants).

Stethoscope Market – Competitive Lanscape:

• 3M Company
• Cardionics, Inc.
• Heine Optotechnik GmbH & Co.
• KG
• American Diagnostics Corp
• Medline Industries, Inc.
• Welch Allyn, Inc.
• GF Health Products, Inc.
• Rudolf Riester GmbH

Stethoscope Market Taxonomy:

By Product Type

• Dual Head Stethoscope
• Single Head Stethoscope
• Triple Head Stethoscope

By Application

• Humans
• Veterinary

By End Users

• Hospitals
• Clinics
• Academic & Institutes
• Homecare settings
• Others

By Region

• North America
• Europe
• Latin America
• Middle East
• Asia Pacific
• Africa

Inquire Here Before Purchase Of This Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1613
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Mechanical Ventilators Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Mechanical Ventilators Market

Mechanical ventilation is a process that helps patients breathe by assisting inhalation of oxygen and exhalation of carbon dioxide through lungs with the help of specialized machines known as mechanical ventilators, respirators or breathing machines. These ventilators are connected to the patients by placing it into the mouth or nose and goes down into the windpipe, whereas some patients undergo surgery to have a hole through which the ventilation pipe can be passed. Mechanical ventilation is a life support treatment that assists the patient with critical health conditions to breathe just enough for the survival. Patients on mechanical ventilators are monitored in an intensive care unit (ICU) settings, which is hooked up to a monitor that measures respiratory rate, blood pressure, heart rate, oxygen saturation, and other critical parameters required for the survival of the patients. The mechanical ventilators does not heal the patient, however, it allows the patient to be stable during the medications and treatments. Healthcare professionals always try to get rid of patients from being monitored on ventilators, as there is a lot of risk involved in it. The process of getting a patient off from the ventilator is termed as weaning.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1605

Market Dynamics:

Rising number of admissions in the intensive care units for continuous monitoring of critical and severely ill patients is expected to boost the market growth. For instance, according to the American Association for the Surgery of Trauma, in 2011, 790,257 hospitalizations involving mechanical ventilation were reported. In 2015, the Centers for Disease Control & Prevention (CDC) stated that acute injury and chronic obstructive pulmonary diseases (COPD) are major disorders responsible for ICU admissions. According to the results of Burden of Obstructive Lung Disease (BOLD) 2014, a multinational study to find prevalence of COPD reported that the prevalence of COPD in Germany was 5.9%, 19.1% in South Africa, and 11.9% in Mexico City of the total country’s population. Moreover, the rise in geriatric population suffering from slow recovery process of various chronic diseases is expected to augment growth of the global mechanical ventilators market. For instance, according to the National Council of Aging, in 2014, around 80% of the adults in the U.S. suffer from at least one chronic condition. The rising demand for emergency treatment of prolonged illness is also expected to drive growth of global mechanical ventilators market. However, high costs of the devices and shrinking profit margins of the major market players are expected to hinder the market growth.

Regional Insights:

On the basis of region, the global mechanical ventilators market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds a dominant position in the global mechanical ventilators market and is expected to retain its dominance over the forecast period, owing to rising number of patient admissions in emergency wards due to critical health conditions and severe injuries that require external support for survival. For instance, according to the Society of Critical Care Medicine, in 2015, over 5.7 million patients were admitted to the intensive care units (ICU) in the U.S. for intensive or invasive monitoring, airway support, stabilization of chronic medical problems, and breathing disorders.

Furthermore, Asia Pacific is expected to witness a significant growth in the market, owing to developments in healthcare infrastructure, rising awareness among patients and manufacturers, and development of innovative and cost efficient solutions. For instance, in September 2017, the department of Neurology at the All India Institute of Medical Sciences (AIIMS) developed a portable life supporting ventilator that is 450 times smaller than the conventional counterparts and multiple times cheaper than the price of normal mechanical ventilators.

Competitive Insights:

The key players operating in the global mechanical ventilators market include Becton, Dickinson & Company, Mindray Medical International Limited, Getinge Group, GE Healthcare, Hamilton Medical AG, Medtronic Plc, Smiths Medical, Draeger Medical GmbH, Philips Respironics, Maquet Medical Systems GmbH, and others. Market players are focused towards providing technologically advanced products to sustain their presence in the market. For instance, in 2016, Maquet Medical Systems introduced two new ventilators named SERVO-U and SERVO-n that provides user-friendly interface to the clinicians dedicated to neonatal intensive care solution.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1605

Market Taxonomy:

On the basis of product type, the global mechanical ventilators market is segmented into:

• Critical Care Mechanical Ventilators
• Neotonal Intensive Care Mechanical Ventilators
• Portable Mechanical Ventilators
• Transport Mechanical Ventilators

On the basis of modality, the global mechanical ventilators market is segmented into:

• Invasive
• Non-Invasive

On the basis of end user, the global mechanical ventilators market is segmented into:

• Hospitals
• Trauma Centers
• Home Healthcare
• Others

On the basis of geography, the global mechanical ventilators market is segmented into:

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of APAC
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Polycystic Ovarian Syndrome Treatment Market Research Report 2026: Effect Factors Analysis, Driving Force, Constraints and Threat Prediction

Polycystic Ovarian Syndrome Treatment Market

Polycystic ovary syndrome is reproductive disorder observed during reproductive age of females. Polycystic ovarian syndrome is depicted by hyperandrogenism, polycystic ovaries and anovulation. There is no cure for polycystic ovarian syndrome. Medical treatments aim to manage and reduce the symptoms or consequences of having polycystic ovarian syndrome with medication for menstrual cycle regulation, infertility treatment, insulin resistance treatment, weight loss treatment and hyperandrogenism. Polycystic ovarian syndrome occurs both in normal-weight and overweight women. However, factors such as insulin resistance (IR), type 2 diabetes, obesity, and cardiovascular disease enhances the chances of polycystic ovarian syndrome occurrence. The factors driving polycystic ovarian syndrome treatment market are increasing funds and grants for research for novel treatment, increasing product approval and pipeline candidates, disease prevalence and high prevalence of risk prone population.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1589

Polycystic Ovarian Syndrome Treatment Market – Driver:

The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.). The acquisition will expand Astellas’ clinical pipeline with fezolinetant, oral compaound for NK3 receptor target. Fezolinetant was in phase IIa clinical trials for the treatment of menopausal hot flashes, polycystic ovary syndrome (PCOS) and uterine fibroids. Moreover, product approval by various approval bodies will expand the treatment option and in turn leading to the market growth. For instance, in 2014, EffRx Pharmaceuticals SA, got US FDA approval for its proprietary metformin-based product candidate, EX404, for pediatric polycystic ovary syndrome (PCOS).

Increasing funding for research and development of novel treatment will also enhance the polycystic ovarian syndrome treatment market during the forecast period. For instance, in 2017, Bayer and the Society for Reproductive Investigation (SRI) launched of the SRI-Bayer Discovery and Innovation Grants Program for supporting research initiatives for addressing unmet medical needs in women’s health. The grant is dedicated to research in endometriois, uterine fibroids and polycystic ovarian syndrome. Further, grants for the treatment of polycystic ovarian syndrome will fuel the market growth. For instance, in 2017, as part of a multi-year endowment from PCOS Diva, the nonprofit organization PCOS Challenge, Inc. will be offering grants up to $500 to help women and girls struggling with hair and skin issues related to polycystic ovary syndrome (PCOS).

Polycystic Ovarian Syndrome Treatment Market - Regional Analysis:

Regional segmentation of polycystic ovarian syndrome treatment market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America market is expected to emerge as the dominant market for polycystic ovary syndrome treatment market owing to a high diagnosis rate, larger number of local players such as AstraZeneca, Teva etc. and high prevalence of the polycystic ovarian syndrome in the region. Asia Pacific is expected to witness fast growth during the forecast period attributing to high population of risk prone individuals.

Polycystic Ovarian Syndrome Treatment Market – Competitor:

• Accord Healthcare Ltd.
• Teva Pharmaceutical Industries Ltd.
• Eisai Pharmaceuticals India Pvt. Ltd (EIL)
• VIVUS, Inc.
• SkinMedica, Inc. (part of Allergan, Inc.)
• Ferring Pharmaceuticals Inc.
• AstraZeneca plc
• EffRx, Inc.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/polycystic-ovarian-syndrome-treatment-market-1589

Polycystic Ovarian Syndrome Treatment Market – Taxonomy:

By Drug Type

• Oral Contraceptives
  • Menopur
  • Bravelle
  • Other Oral Contraceptives
• Antiandrogens
• Insulin-sensitizing Agent
  • Pioglitazone
  • Rosiglitazone
  • Other Insulin-sensitizing Agents
• Anti-obesity Drugs
  • Xenical
  • Qsymia
  • Belviq
  • Other Anti-Obesity Drugs
• Other

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Inquire Here Before Purchase Of This Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1589

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Adrenocortical Carcinoma Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Adrenocortical Carcinoma Treatment Market

Adrenocortical carcinoma is a rare cancer affecting the outer layer of the adrenal glands, which are responsible for producing certain hormones and maintaining optimum blood pressure levels. Adrenocortical carcinoma is relatively frequent in children compared to other cancers, although the cancer may also affect adults. The most common symptoms of adrenocortical carcinoma include abdominal pain, hypertension, weight gain, and frequent urination, which are mainly caused due to tumors causing excess secretion of hormones from the adrenal glands. Mitotane is the only drug approved by the U.S. Food and Drug Administration (FDA) and European Medicine Executive Agency (EMEA) for treatment of metastatic adrenocortical carcinoma. According to the study by HealthLine Media, 2017, about 5-10% of the adrenal tumors are malignant. Diagnosis of adrenocortical carcinoma is based on urine tests, dexamethasone suppression test for detecting abnormal levels of cortisol, which is the hormone released by the adrenal glands. Also, a wide number of imaging devices are used for diagnoses of the disease, which includes CT scan, MRI, PET scan, and MIBG Scan, thus aiding for faster disease identification that aids the doctors to decide for further treatments.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1551

Adrenocortical Carcinoma Treatment Market: Market Dynamics

Increasing incidence of adrenocortical carcinoma associated with genetic disorders is a major factor augmenting growth of the adrenocortical carcinoma treatment market. According to the Journal of Clinical Endocrinology & Metabolism, 2013, the peak incidence of adrenocortical carcinoma ranges between 40-50 years, where women are 55–60% more likely to get affected with a ratio of ratio 1.5:1. The study also states that adrenocortical carcinoma is a rare and highly aggressive malignancy with an annual incidence of 0.05–0.2% or 1-2 cases per million population globally. Also, inherited disorders such as Li-Fraumeni syndrome (LFS), Beckwith-Wiedemann syndrome (BWS), and Carney complex are linked with increasing incidence of adrenocortical carcinoma. According to the survey by Endocrine Society, 2014, adrenocortical carcinoma comprises an approximate 3% to 10% of malignancies in LFS and over 5-15% of malignancies in BWS. Moreover, according to the study by Medscape, 2017, adrenocortical carcinoma accounted for 0.02-0.2% of all cancer-related deaths, globally.

Adrenocortical Carcinoma Treatment Market: Regional Dynamics

Regional segmentation of the global adrenocortical carcinoma treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global adrenocortical carcinoma treatment market over the forecast period, owing to rise in prevalence of the disease and presence of key players that are focusing on developing novel products, followed by Europe, the next dominating adrenocortical carcinoma treatment market. According to the National Institutes of Health Office of Rare Diseases Research, the incidence rate of adrenal cancer is about 600 new cases per year in the U.S. Moreover, organizations such as the University of Michigan Rogel Cancer Center are involved in stem cell research, to advance treatment in adrenal cancer.

Latin America is expected to gain significant traction in the forecast period, owing to higher incidence rate of the condition in Brazil. According to the survey ACC C.U.R.E. Organization, adrenal cancer in Brazil is 15 times more prevalent than any other countries in the world, attributed to high prevalence of mutation of a single gene TP53. Also, according to the Endocrine Society, 2014, the incidence during childhood is 2.9 to 4.2 per million per year in Brazil compared with an estimated incidence of 0.2 to 0.3 per million children per year worldwide. Moreover, the University of Michigan has been collaborating with the Adrenal Cancer Group in Sao Paulo to bring about the advancements in adrenal cancer research, thus providing better clinical outcomes for patients in the region.

Adrenocortical Carcinoma Treatment Market: Competitive Analysis

Manufactures are focused on launching novel therapeutic products for treatment of these rare diseases, thus accelerating market growth. For instance, in 2017, the FDA approved immunotherapy drug Keytruda (Pembrolizumab), the first anti-PD-1 (programmed death receptor-1) therapy, developed by Merck & Co., indicated for advanced adrenocortical carcinoma.

Key players operating in the global adrenocortical carcinoma treatment market include ArQule, Inc., EnGeneIC Ltd., Exelixis, Inc., Merck & Co., Millendo Therapeutics, and Orphagen Pharmaceuticals, Inc.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1551

Adrenocortical Carcinoma Treatment Market:Market Taxonomy

On the basis of therapy type, the global adrenocortical carcinoma treatment market is segmented into:

• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Adjuvant Therapy

On the basis of disease type, the global adrenocortical carcinoma treatment market is segmented into:

• Localized adrenocortical carcinoma
• Metastatic adrenocortical carcinoma

On the basis of end user, the global adrenocortical carcinoma treatment market is segmented into:

• Hospital
• Clinics
• Ambulatory Surgical Centers

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Colposcope Market: How The Market Will Perform In Upcoming Years Based On Market Size, Share And Demand In Major Regions | 2018-2026

Colposcope Market

Colposcopy is a diagnostic method useful for the diagnosis and evaluation of cervical intraepithelial neoplasia and preclinical invasive cancer. It allows magnified visualization of the site where cervical carcinogenesis occurs. Colposcope is a magnifying instrument used in the diagnosis of cervical cancer or vaginal cancer. Colposcope can also be used to take small tissue sections for further diagnosis via biopsy. Colposcopy is a diagnostic method usually performed after the Pap smear test. Increasing prevalence of cervical and vaginal cancer is expected to boost demand for colposcopy, in turn, boosting growth of the Colposcope market. Moreover, increasing number of government initiatives such as screening programmes to increase awareness about cancer is also expected to fuel growth of the colposcope market. Availability of alternative methods for detection of cervical and vaginal cancer such as Pap smear test and HPV test hinder growth of the colposcope market. The high cost of colposcope devices is also a factor expected to hinder market growth.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1494

Colposcope Market Driver:

In several emerging economies in Africa and Asia, record high risk of cervical cancer among women, and largely lack detection programmes and efficient screening programmes. In these regions, governmental initiatives for cervical cancer screening and increasing healthcare providers with skills in cervical cancer prevention are important components of global cervical cancer control initiatives which is leading to growth of the colposcope market. According to Centers for Disease Control and Prevention (CDC), 2014 data, 4115 women died due to cervical cancer in the U.S. owing to the growing death rate due to cancer, governments of developed economies are continuously focusing on increasing awareness among the populace about screening programmes and make them accessible, to decrease the rate of mortality caused by genital cancer. For instance, Cancer Institute NSW of Australia, state-wide government-supported cancer control agency, renewed National Cervical Screening Program in 2017, which aims to reduce incidence and mortality caused by cervical cancer by organizing screening programmes. Moreover, according to British Journal of Cancer, cervical diagnostic conducted in 2007- 2013 shows 67% reduction in stage 1A and 95% in stage 3 as compare to 1988 in women of age group 35-64 year, in England. These can be attributed to successful comprehensive screening program that incorporates nationwide education campaign, effective screening methods, including Papanicolaou (Pap) smear and human papillomavirus (HPV) testing, and advanced diagnostic and treatment technologies. Moreover, 7 UN agencies established a new 5-year Joint Programme to prevent and control cervical cancer.

The colposcope market is expected to show potential growth during the forecast period due to rising prevalence of cervical and vaginal cancer, globally. This in turn, is expected to increase the demand for colposcope for diagnostics. For instance, cervical cancer is the fourth most common cancer worldwide among women, with 528,000 new cases and 266,000 deaths in 2012, according to International Agency for Research on Cancer (IARC). Furthermore, advancements in technology also plays an important role in boosting growth of the colposcope market. Currently high cost of these devices and lack of skilled professional are restraints for this colposcope market. Increasing research and development by various manufacturers, to create cost-effective devices, is further expected to propel growth of the market. For instance, in 2017, Duke University in collaboration with 3^rd Stone Design, Inc., developed a beta prototype of the Pocket Colposcope, which is significantly less expensive, smaller in size and lighter than traditional clinical colposcope devices.

Colposcope Market – Regional Analysis:

The colposcope market is geographically segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America holds a prominent position in the colposcope market, attributed to the presence of major players and high adoption of medical technology in the region. Asia Pacific is expected to hold the fastest-growing market for colposcope due to high prevalence of cervical cancer in low and middle income countries. According to National Center for Biotechnology Information, in 2014, 122,844 women are diagnosed with cervical cancer every year in India, whereas 432.2 million women aged 15 years or above are at risk of developing cancer. This in turn, is expected to favor growth of colposcope market.

Colposcope Market – Competitors:

Major players operating in the colposcope market include,

• DySIS
• CooperSurgical
• Atmos
• Olympus
• Karl Kaps
• McKesson
• Danaher
• Carl Zeiss

Colposcope Market Taxonomy:

By Product Type:

• Optical Colposcope
• Digital Colposcope

By Portability:

• Trolley Mounted
• Chair Mounted
• Handheld

By End Users:

• Hospitals
• Clinics
• Diagnostic Centers
• Others

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/1494

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Cervical Dysplasia Diagnostic Market Increasing Demand, New Developments & Market Toppers Till 2026

Cervical Dysplasia Diagnostic Market

Cervical dysplasia is a precancerous condition characterized by abnormal growth of endocervical canal cells. Cervical dysplasia is also called as cervical intraepithelial neoplasia. It is a Sexually Transmitted Disease (STD) caused due to human papillomavirus (HPV) infection. Cervical dysplasia can be of two types based on the type of cells it affect - squamous intraepithelial lesion and glandular cell lesions. It occurs in all age groups and it is common in women with 30 years age. Cervical dysplasia can be detected by Pap test, endocervical curettage, and loop electrosurgical excision procedure (LEEP) or HPV DNA test. The cervical dysplasia diagnostic market is expected to witness significant growth over the forecast period, owing to increasing prevalence of disease and increasing awareness regarding utilization of detection test through government screening programmes for regular screening for human papillomavirus. Moreover, high accuracy of HPV test at low cost is expected to fuel growth of the HPV test segment in cervical dysplasia diagnostic market.

Request Sample Copy of Research Report @https://www.coherentmarketinsights.com/insight/request-sample/1486

Market Driver:

Cervical infection is major risk factor for progression of HPV. Currently, conventional Pap smear test or HPV test are the only test available for screening cervical infection, which in turn propels the demand for development of DNA-based molecular testing to detect human papillomavirus for diagnosis of cervical cancer. For instance, in 2016, Becton, Dickinson and Company received pre-diagnostic market approval from FDA for its Onclarity HPV assay, type of HPV test. However, current practices for cervical dysplasia diagnostic through colposcopy requires trained professional to perform the test, which is major challenge for growth of the market. To overcome this, research institutes and universities are involved in development of innovative diagnosis devices, which in driving growth of the cervical dysplasia diagnostic market. For instance, in July 2017, Duke University in North Carolina developed a pocket colposcopy device enable with laptop and mobile connection. The device was funded by National Institutes of Health (NIH).

The untreated cervical dysplasia progresses into cervical cancer or cervical carcinoma, which is the leading cause of cancer death for women in the US. According to American Society of Clinical Oncology (ASCO), in 2017, an estimated 12,820 women in the U.S. are expected to be diagnosed with cervical cancer along with 4210 deaths every year. Furthermore, ASCO reported 68% increase in survival rate of cervical cancer patients, which suggest increasing use of cervical dysplasia diagnostic and boosting cervical dysplasia diagnostic market to prevent the cervical cancer. Moreover, Europe witnessed high prevalence of cervical cancer. For instance, in 2012, the incidence of cervical cancer in Europe was 58348 individuals per millions, increased by rate of 13.4% whereas mortality was raised by 4.9%. Moreover, government organisation of emerging economies are involved in spreading awareness and conducting screening test for cervical dysplasia, which is expected to drive growth of the cervical dysplasia diagnostic market. Organisations such as National Health Service (NHS) offers cervical screening programmes since 1980s, at the interval of every three year for women of age group 25 to 64 year and every five year above 64 in England, wales and northern Ireland.

On the basis of region, cervical dysplasia diagnostic market is segmented into North America, Europe, Asia Pacific, South America, and Middle East. Increasing awareness regarding cervical dysplasia screening programs and technological advancements in screening are the key factors fuelling growth of the North America cervical dysplasia diagnostic market. Moreover, market in Asia Pacific region is expected to witness significant growth over the forecast period, owing to increasing government funding for cervical research and improving healthcare infrastructure.

Request For Customization of Research Report @https://www.coherentmarketinsights.com/insight/request-customization/1486

Abbott Laboratories, Qiagen N.V., Hologic Inc., F. Hoffmann La-Roche Ltd., Quest Diagnostics Inc., Becton, Dickinson and Company, Atmos, and Karl Kaps are the major players involved in cervical dysplasia diagnostic market.

Cervical Dysplasia Diagnostic Market Taxonomy:

By Diagnostic

• Diagnostic Test
• Pap smear Test
• HPV Test
• Biopsy Test
  • Exocervical Biopsy
  • Endocervical Biopsy
• Diagnostic Device
• Colposcope

By End Users

• Hospitals & Clinics
• Diagnostic Centers
• Ambulatory Surgical Centers

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various ecommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com